Activity of 'Seroquel' (ICI 204,636) in animal models for atypical properties of antipsychotics: A comparison with clozapine

Neuropsychopharmacology

Volumn 15, Issue 4, 1996, Pages 406-416

  Ellenbroek, Bart A ^a   Lubbers, Luuk J ^a   Cools, Alexander R ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Clozapine; ICI 204,636; Monkey social isolation; Paw test; Schizophrenia; Seroquel

Indexed keywords

AMPHETAMINE; CLOZAPINE; NEUROLEPTIC AGENT; QUETIAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MONKEY; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SOCIAL ISOLATION;

EID: 0030272376     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(96)00001-2     Document Type: Article

References (44)

1. Albus M, Botschev C, Muller-Spahn R, Naber D, Munch U, Ackenheil M (1986): Clinical and biochemical effects of necergoline in chronic schizophrenic patients. Pharmacopsychiatry 19:101-105
2. Angrist B, Rotrosen J, Gershon S (1980): Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacology 72: 17-19
3. Arvanitis L, Miller BG, Link CGC (1995): Seroquel (ICI 204 636): A novel atypical antipsychotic: Efficacy and safety results from two phase II, multicenter, placebo controlled clinical trials. Schizophr Res 15:142
4. Borison RL, Arvanitis LA, Millrt BG (1996): ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Pharmacol, in press
5. Cools AR, Prinssen EPM, Ellenbroek BA (1995): The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: Effects of risperidone, prothipendyl, ORG 5222, sertindole, and olanzapine. Psychopharmacology 119:428-439
6. Csernansky JG, Riney S, Lombrozo L, Overall J, Hollister, LE (1988): Double blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. Arch Gen Psychiatry 45:655-659
7. Den Boer JA, van Megen HJGM, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HGM, Burrows GD, Srivastava ON: (1995) Differential effects of the D1-DA receptor antagonist SCH39161 on positive and negative symptoms of schizophrenia. Psychopharmacology 121: 317-322
8. Ellenbroek BA (1991): The ethological analysis of monkeys in a social setting as an animal model for schizophrenia. In Olivier B, Mos J, Slangen J (eds), Animal Models in Psychopharmacology. Base, Birkhäuser Verlag, pp 265-284
9. Ellenbroek BA (1993): Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 57:1-78
10. Ellenbroek BA, Cools A (1988): The paw test: An animal model for neuroleptic drugs which fulfils the criteria for pharmacological isomorphism. Life Sci 42:1205-1213
11. Ellenbroek BA, Peeters BW, Honig W, Cools AR (1987): The paw test: A behavioral paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology 93:343-348
12. 1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys. Neuropsychopharmacology 2:191-199
13. 2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur J Pharmacol 196:103-108
14. Ellenbroek BA, Prinssen EPM, Cools AR (1994): The role of serotonin receptor subtypes in the behavioral effects of neuroleptic drugs. A paw test study in rats. Eur J Neurosci 6:1-8
15. Fabre LF (1993): A multicenter, open, pilot trial of ICI 204 636 in hospitalized patients with acute psychotic symptomatology. Schizophr Res 9:237
16. ™ (ICI 204,636), a novel, atypical antipsychotic: Early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 17:366-378
17. Githin MJ, Gerner R, Rosenblatt M (1981): Assessment of naltrexone in the treatment of schizophrenia. Psychopharmacology 74:51-53
18. Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993): Seroquel: Electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 112:293-298.
19. Haber S, Barchas P, Barchas J (1977): Effects of amphetamine on social behaviors of Rhesus macaques: An animal model of paranoia. In Hanin I, Usdin E (eds), Animal Models in Psychiatry and Neurology. New York, Pergamon Press, pp 197-115
20. Haller E, Binder R (1990): Clozapine and seizures. Am J Psychiatry 147:1069-1071
21. Hirsch SR (1994): "ICI 204,636": An example of an atypical antipsychotic drug. Neuropsychopharmacology 10:371S
22. Johnstone E, Crow T, Frith C, Carney C, Price J (1978): Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1:848-851
23. Kane JM (1995): Psychopharmacologic approaches to the treatment of schizophrenia: Practical aspects. In DenBoer JA, Westenberg HGM, van Praag HM (eds), Advances in the Neurobiology of Schizophrenia. Chichester, John Wiley & Sons, pp 245-263
24. Kane JM, Honigfeldt G, Singer J, Meltzer H (1988): Clozapine in treatment resistant schizophrenics. Psychopharmacol Bull 24:62-67
25. Knobbout DA, Ellenbroek BA, Cools AR (1996): The influence of social structure on social isolation in amphetamine-treated JAVA-monkeys (Macaca Pascicularis). Behav Pharmacol (in press).
26. Kucharski L, Alexander P, Tune L, Coyle J (1984): Serum neuroleptic concentrations and clinical response: A radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology 82:194-198
27. Leysen JE, Gommeren W, Eens A, DeChaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988): Biochemical profile of risperidone: A new antipsychotic. J Pharmacol Exp Ther 247:661-670
28. 2 antagonists: A preclinical evaluation of possible therapeutic effects. In Idzikowski C, Cowen PJ (eds), Serotonin, Sleep and Mental Disorders. Wrightson Biomedical Publishing, pp 65-76
29. Mereu GM, Lilliu V, Vargiu P, Muntoni AL, Diana M, Gessa GL (1995): Depolarization inactivation of dopamine neurons: An artifact? J Neurosci 15:1144-1149
30. Miczek K, Yoshimura H (1982): Disruption of primate social behavior by d-amphetamine and cocaine: Differential antagonism by antipsychotics. Psychopharmacology 76:163-171
31. Migler G, Warana E, Malick J (1993): ICI 204,636: Behavioural effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 112:299-307
32. Myers D, Campbell P, Cocks N, Flowerder J, Muir A (1981): A trial of propranolol in chronic schizophrenia. Br J Psychiatr 139:118-121
33. Prinssen EPM, Ellenbroek BA, Cools AR (1994a): Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test. Br J Pharmacol 112:769-774
34. Prinssen EPM, Ellenbroek BA, Cools AR (1994b): Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur J Pharmacol 262:167-170
35. 2 receptors in the paw test, an animal model for the therapeutic efficacy and extrapyramidal side effects of neuroleptic drugs. Brain Res 673:283-289
36. Ridley R, Baker H, Scraggs P (1979): The time course of the behavioural effects of amphetamine and their reversal by haloperidol in a primate species. Biol Psychiatry 14:753-765
37. Saller C, Salama A (1993): ICI 204,636: Biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285-292
38. Schiorring E (1979): Changes in individual and social behavior induced by amphetamine and related compounds in monkeys and man. In Ellinwood E, Kilbey M (eds), Cocaine and Other Stimulants. New York, Plenum Press, pp 481-522
39. Schlemmer RF, Davis JM (1981): Evidence for dopamine mediation of submissive gestures in stumptailed macaque monkeys. Pharmacol Biochem Behav 14(suppl 1):95-102
40. Scottish Schizophrenia Research Group (1987): The Scottish first episode schizophrenia study. Br J Psychiatry 150: 331-344
41. Scraggs P, Ridley R (1979): The effect of dopamine and noradrenaline blockade on amphetamine-induced behavior in the marmoset. Psychopharmacology 62:41-45
42. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L, Jones T, Frackowiak RSJ (1995): A functional neuroanatomy of hallucinations in schizophrenia. Nature 378:176-179.
43. Wetzel H, Szegedi A, Hain Ch, Wiesner J, Schlegel S, Benkert O (1995): ICI 204,636 (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: Results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 119:231-238
44. Winslow J, Miczek K (1988): Naltrexone blocks amphetamine-induced hyperactivity but not disruption of social and agonistic behavior in mice and squirrel monkeys. Psychopharmacology 96:493-499